Use of attenuated bacteria as delivery vectors for DNA vaccines

References

• Liu MA. DNA vaccines: a review. J. Int. Med.253, 402–410 (2003).
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Immunization without needles. Nat. Rev. Immunol.5, 905–916 (2005).
   PubMed Web of Science ®Google Scholar
• Lowe DB, Shearer MH, Kennedy RC. DNA vaccines: successes and limitations in cancer and infectious disease. J. Cell Biochem.98, 235–242 (2006).
   PubMed Web of Science ®Google Scholar
• Dietrich G, Griot M, Metcalfe IC, Lang AB, Viret J. Experience with registered mucosal vaccines. Vaccine21, 678–683 (2003).
   PubMed Web of Science ®Google Scholar
• Germanier R, Fürer E. Isolation and characterization of Gal E mutant Ty21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis.131, 553–558 (1975).
   PubMed Web of Science ®Google Scholar
• Levine MM, Galen J, Barry E et al. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J. Biotechnol.44, 193–196 (1996).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Hone DM, Curtiss R III et al. Comparison of the safety and immunogenicity of Δ aroC Δ aroD and Δ cya Δ crp Salmonella typhi strains in adult volunteers. Infect. Immun.60, 536–541 (1992).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Losonsky GA et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun.65, 452–456 (1997).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Wasserman SS et al. Phase II clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun.68, 1196–1201 (2000).
   PubMed Web of Science ®Google Scholar
• Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest.90, 412–420 (1992).
   PubMed Web of Science ®Google Scholar
• Dilts DA, Riesenfeld-Orn I, Fulginiti JP et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine18, 1473–1484 (2000).
   PubMed Web of Science ®Google Scholar
• Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine14, 19–24 (1996).
   PubMed Web of Science ®Google Scholar
• Curtiss R III, Kelly SM. Salmonella typhimurium deletions mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun.55, 3035–3043 (1987).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Kelly SM, Schodel F et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun.65, 3381–3385 (1997).
   PubMed Web of Science ®Google Scholar
• Hindle Z, Chatfield SN, Phillimore J et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun.70, 3457–3467 (2002).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, McKenzie R, O’Neill JP et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine24, 116–123 (2006).
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun.68, 2135–2141 (2000).
   PubMed Web of Science ®Google Scholar
• DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine18, 449–459 (1999).
   PubMed Web of Science ®Google Scholar
• Li A, Pal T, Forsum U, Lindberg AA. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine10, 395–404 (1992).
   PubMedGoogle Scholar
• Li A, Cam PD, Islam D et al. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. J. Infect. Dis.28, 11–23 (1994).
   Google Scholar
• Li A, Karnell A, Huan PT et al. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine11, 180–189 (1993).
   PubMedGoogle Scholar
• Karnell A, Li A, Zhao CR, Karlsson K, Nguyen BM, Lindberg AA. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine13, 88–99 (1995).
   PubMedGoogle Scholar
• Coster TS, Hoge SW, Van De Verg LL et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun.67, 3437–3443 (1999).
   PubMed Web of Science ®Google Scholar
• Katz DE, Coster TS, Wolf MK et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun.72, 923–930 (2004).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Taylor DN, Sztein MB et al. Phase I evaluation of Δ virGShigella sonnei live, attenuated vaccine strain WRSS1 in healthy adults. Infect. Immun.70, 2016–2012 (2002).
   PubMed Web of Science ®Google Scholar
• Orr N, Katz DE, Atsmon J et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect. Immun.73, 8027–2032 (2005).
   PubMedGoogle Scholar
• Kotloff KL, Noriega FR, Samandari T et al.Shigella flexneri 2a strain CVD1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun.68, 1034–1039 (2000).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Noriega F, Losonsky GA et al. Safety, immunogenicity and transmissibility in humans of CVD1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun.64, 4542–4548 (1996).
   Google Scholar
• Kotloff KL, Pasetti MF, Barry EM et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in Phase I trial of CVD 1204 and CVD 1208. J. Infect. Dis.190, 1745–1754 (2004).
   PubMed Web of Science ®Google Scholar
• Roland KL, Tinge SA, Killeen KP, Kochi SK. Recent advances in the development of live attenuated bacterial vectors. Curr. Opin. Mol. Therap.7, 62–72 (2005).
   PubMedGoogle Scholar
• Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes.Nat. Biotechnol.16, 181–185 (1998).
   PubMed Web of Science ®Google Scholar
• Pilgrim S, Stritzker J, Schoen C et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther.10, 2036–2045 (2003).
   PubMed Web of Science ®Google Scholar
• Loeffler DIM, Schoen CU, Goebel W, Pilgrim S. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Inf. Immun.74, 3946–3957 (2006).
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Loock K, Sisul DM et al. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun.70, 3592–3601 (2002).
   PubMed Web of Science ®Google Scholar
• Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol.294, 319–335 (2004).
   PubMed Web of Science ®Google Scholar
• Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J. Pathol.208, 290–298 (2006).
   PubMed Web of Science ®Google Scholar
• Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri strain. J. Immunol.162, 1603–1610 (1999).
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Barry EM, Losonsky G et al. Attenuated Salmonella enterica serovar typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol.77, 5209–5217 (2003).
   PubMed Web of Science ®Google Scholar
• Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine20, 623–629 (2002).
   Google Scholar
• Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T-cells and antiviral protective immunity. J. Virol.75, 9665–9670 (2001).
   PubMed Web of Science ®Google Scholar
• Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol. Lett.82, 197–204 (2002).
   PubMed Web of Science ®Google Scholar
• Karpenko LI, Nekrasova NA, Ilyichev AA et al. Comparative analysis using a mouse model of the immunogenicity of artifical VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine22, 1692–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Miki K, Nagata T, Tanaka T et al. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect. Immun.72, 2014–2021 (2004).
   PubMed Web of Science ®Google Scholar
• Parida SK, Huygen K, Ryffel B, Chakraborty T. Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization. Establishment of proof of principle in TB mouse model. Ann. NY Acad. Sci.1056, 366–378 (2005).
   PubMed Web of Science ®Google Scholar
• Galen JE, Levine MM. Can a ‘flawless’ live vector vaccine strain be engineered? Trends Microbiol.9, 372–376 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cott JL, Chatfield SN, Roberts M et al. Regulation of host immune responses by modification of Salmonella virulence genes. Nat. Med.4, 1247–1252 (1998).
   PubMed Web of Science ®Google Scholar
• Raupach B, Kurth N, Pfeffer K, Kaufmann SH. Salmonella typhimurium strains carrying independent mutations display similar virulence phenotypes yet are controlled by distinct host defense mechanism. J. Immunol.170, 6133–6140 (2003).
   PubMedGoogle Scholar
• Coulson NM, Fulop M, Titball RW. Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent Salmonella typhimurium SL3261. Microb. Pathog.16, 305–311 (1994).
   PubMed Web of Science ®Google Scholar
• Dunstan SJ, Simmons CP, Strugnell RA. In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. Typhimurium. FEMS Immunol. Med. Microbiol.37, 111–119 (2003).
   PubMedGoogle Scholar
• Spreng S, Viret JF. Plasmid maintenance systems suitable for GMO-based bacterial vaccines. Vaccine23, 2060–2065 (2005).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Brown KA, Titball RW. DNA vaccines: improving expression of antigens. Genet. Vaccines Ther.1, 2 (2003).
   PubMedGoogle Scholar
• Zelmer A, Krusch S, Koschinski A et al. Functional transfer of eukaryotic expression plasmids to mammalian cells by Listeria monocytogenes: a mechanistic approach. J. Gene Med.7, 1097–1112 (2005).
   PubMedGoogle Scholar
• Xiang R, Lode HN, Chao TH et al. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl Acad. Sci. USA97, 5492–5497 (2000).
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Xiang R, Ruehlmann JM et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res.61, 6178–6184 (2001).
   PubMed Web of Science ®Google Scholar
• Weth R, Christ O, Stevanovic S, Zoller M. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther.8, 599–611 (2001).
   PubMed Web of Science ®Google Scholar
• Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol. Lett.80, 89–96 (2002).
   PubMed Web of Science ®Google Scholar
• Huebener N, Lange B, Lemmel C et al. Vaccination with minigenes encoding for novel ‘self’ antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett.197, 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a post-transcriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood101, 649–654 (2003).
   PubMed Web of Science ®Google Scholar
• Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol.35, 641–646 (2000).
   PubMedGoogle Scholar
• Xiang R, Primus FJ, Ruehlmann JM et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J. Immunol.167, 4560–4565 (2001).
   PubMed Web of Science ®Google Scholar
• Xiang R, Siletti S, Lode HN et al. Protective immunity against carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer Res.7, 856s–864s (2001).
   PubMedGoogle Scholar
• Niethammer AG, Primus FJ, Xiang R et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine20, 421–429 (2002).
   Google Scholar
• Reisfeld RA, Niethammer AG, Luo Y, Xiang R. DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int. Arch. Allergy Immunol.133, 295–304 (2004).
   PubMedGoogle Scholar
• Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med.8, 1369–1375 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood106, 2026–2032 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SH, Mizutani N, Mizutani M et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother.55, 1565–1574 (2006).
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Krueger J et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest.116, 2132–2141 (2006).
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Wodrich H, Loeffler M et al. Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J.19, 158–169 (2005).
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res.65, 5027–5030 (2005).
   PubMed Web of Science ®Google Scholar
• Urashima M, Suzuki H, Yuza Y, Akiyama M, Ohno N, Eto Y. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood95, 1258–1263 (2000).
   PubMed Web of Science ®Google Scholar
• Yuhua L, Kunyuan G, Hui C et al. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int. J. Cancer94, 438–443 (2001).
   PubMed Web of Science ®Google Scholar
• Feng K-K, Zhao H-Y, Qiu H, Liu J-X, Chen J. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett.221, 41–47 (2005).
   PubMedGoogle Scholar
• Paglia P, Terrazzini N, Schulze K, Guzman CA, Colombo MP. In vivo correction of genetic defects of monocyte/macrophage using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther.7, 1725–1730 (2000).
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc. Natl Acad. Sci. USA100, 8850–8855 (2003).
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Mizutani M et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res.65, 3419–3427 (2005).
   PubMedGoogle Scholar
• Xiang R, Mizutani N, Luo Y et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res.65, 553–561 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou H, Luo Y, Lo JF et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc. Natl Acad. Sci. USA102, 10846–10851 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou H, LuoY, Kaplan CD et al. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood107, 3251–3257 (2006).
   PubMedGoogle Scholar
• European Medicines Agency. Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. EMEA/CPMP/BWP/3088/99 (2001).
   Google Scholar
• World Health Organization. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines (2005).
   Google Scholar
• Food and Drug Administration. Points to consider on plasmid DNA vaccines for preventive infectious disease indications. (1997).
   Google Scholar
• Detmer A, Glenting J. Live bacterial vaccines – review and identification of potential hazards. Microb. Cell Fact.5, 23 (2006).
   PubMed Web of Science ®Google Scholar
• Lindberg AA. The history of live bacterial vaccines. Dev. Biol. Stand.84, 211–219 (1995).
   PubMedGoogle Scholar
• Favre D, Viret JF. Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. Vaccine24, 3856–3864 (2006).
   PubMed Web of Science ®Google Scholar
• Davison J. Towards safer vectors for the field release of recombinant bacteria. Environ. Biosafety Res.1, 9–18 (2002).
   PubMedGoogle Scholar
• Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J. Bacteriol.177, 7011–7018 (1995).
   PubMed Web of Science ®Google Scholar
• Ledwith BJ, Manam S, Troilo PJ et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology43, 258–272 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J. Autoimm.9, 699–703 (1996).
   PubMed Web of Science ®Google Scholar
• Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine20, 1968–1974 (2002).
   PubMed Web of Science ®Google Scholar